2,529 results on '"Joe, W."'
Search Results
2. Novel genetic loci associated with osteoarthritis in multi-ancestry analyses in the Million Veteran Program and UK Biobank
3. Systems Biology and Genomics
4. A Framework to Segment Cellular Ultrastructure from 3D Electron Microscopy Images of Human Biopsies
5. (+)‐Catechin Attenuates Multiple Atherosclerosis‐Associated Processes In Vitro, Modulates Disease‐Associated Risk Factors in C57BL/6J Mice and Reduces Atherogenesis in LDL Receptor Deficient Mice by Inhibiting Inflammation and Increasing Markers of Plaque Stability
6. Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
7. Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme
8. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
9. Supplementary Table 4 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
10. Data from Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer
11. Supplementary Movie from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
12. Supplementary Methods, Figures 1-4, Movie Legend, Table Legends 1-5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
13. Supplementary Methods from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
14. Supplementary Figure 4 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
15. Supplementary Table S1 from Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer
16. Data from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
17. Supplementary Materials and Methods from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
18. Supplementary Table 1 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
19. Supplementary File 4_Reactome Pathway Analysis from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
20. Supplementary Data from Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer
21. Supplementary Figures S1-S7 from Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform
22. Supplementary File 2_Gene Sets from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
23. Supplementary Figure 5 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
24. Supplementary Figure 1 from Temporal Dissection of Tumorigenesis in Primary Cancers
25. Supplementary Figure 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
26. Supplementary Figure Legends 1-4, Methods from Temporal Dissection of Tumorigenesis in Primary Cancers
27. Supplementary Table 1 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
28. Supplementary File 3_Core Enriched Genes from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
29. Supplementary Table 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
30. Supplementary Figure 5 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
31. Supplementary Figure 7 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
32. Supplementary Figures S1-S3 from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
33. Supplementary Figure 1 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
34. Supplementary Figure 6 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
35. Supplementary Figure 3 from Temporal Dissection of Tumorigenesis in Primary Cancers
36. Supplementary Figure 3 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
37. Supplementary Table 5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
38. Supplementary Data from Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer
39. Supplementary Methods from Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform
40. Supplementary Table 2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
41. Supplementary Materials and Methods from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
42. Supplementary Figure Legends 1-5, Table Legends 1-2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
43. Supplementary Figure 4 from Temporal Dissection of Tumorigenesis in Primary Cancers
44. Supplementary Table 2 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
45. Supplementary File 1_Rank List from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
46. Supplementary Figures S4-S12 from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
47. Supplementary Tables S1-S4 from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
48. Supplementary Table 1 from Temporal Dissection of Tumorigenesis in Primary Cancers
49. Supplementary Table 3 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
50. Supplementary Figure 3 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.